Israel - Ibrani - Ministry of Health

taro international ltd - anastrozole 1 mg - tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

Israel - Ibrani - Ministry of Health

sam-on ltd - anastrozole 1 mg - film coated tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

Israel - Ibrani - Ministry of Health

sam-on ltd - anastrozole 1 mg - film coated tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

Israel - Ibrani - Ministry of Health

perrigo israel agencies ltd - anastrozole 1 mg - film coated tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

Israel - Ibrani - Ministry of Health

perrigo israel agencies ltd - anastrozole 1 mg - film coated tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

Israel - Ibrani - Ministry of Health

megapharm ltd - hydrocortisone acetate; pramocaine hydrochloride - קצף - pramocaine hydrochloride 0.9363 %w/w; hydrocortisone acetate 0.9363 %w/w - relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Israel - Ibrani - Ministry of Health

teva israel ltd - letrozole - טבליה - letrozole 2.5 mg - letrozole

Israel - Ibrani - Ministry of Health

teva pharmaceutical indust.ltd - letrozole 2.5 mg - tablets - letrozole - letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Israel - Ibrani - Ministry of Health

perrigo israel agencies ltd - letrozole 2.5 mg - film coated tablets - letrozole - • femozol (letrozole tablets) is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer . • femozol is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy .• extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy .• adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer .

Israel - Ibrani - Ministry of Health

inovamed ltd - letrozole 2.5 mg - film coated tablets - letrozole - for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined locally advanced or metastatic breast cancer. for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy.adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.